Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
South Korea’s KOSPI Jumps Over 5% as Samsung, SK Hynix Rally on Micron Earnings Boost 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
White House Seeks $87.6 Billion Emergency Funding for Iran War, Farmers, and Ebola Response 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Johnson & Johnson is set to pay $230 million to settle a legal case over claims it encouraged and bolstered the opioid addiction predicament in the state of New York. Then again, it was mentioned that despite settling, the company did not acknowledge liability or any wrongdoing in what it was accused of.
What the J&J settlement means
As per BBC News, Johnson & Johnson settlement effectively prevented it from going to trial that is set to start on Tuesday, June 29. The hearing will present a number of opioid manufacturers and distributors as the defendants of the case.
The company said that its agreements with New York State are proportionate with the previous resolution to pay $5 billion to settle the opioid claims. It was added that the arrangement also requires Johnson & Johnson to discontinue the sale of painkillers across the country.
"The opioid epidemic has wreaked havoc on countless communities across New York state and the rest of the nation, leaving millions still addicted to dangerous and deadly opioids," Letitia James, the New York attorney general, said. "Johnson & Johnson helped fuel this fire, but today they're committing to leaving the opioid business - not only in New York but across the entire country."
J&J to take its problematic painkillers off the market
It was mentioned that addiction to opioids, both legal and illegal drugs, has become a serious issue, and this problem is ongoing in countries like the United States. In fact, based on the record of the Centers for Disease Control and Prevention, the country reported almost half a million deaths due to overdoses between the years 1999 and 2019.
While Johnson & Johnson is set to be removed from the trial in New York, it is still facing similar cases in other states such as California. At any rate, the deal with New York also asked the company to stop selling opioids, and it was learned that J&J already did so for some time now.
CNBC reported that Johnson & Johnson confirmed it has ended its opioid business a while ago, even before the settlement with New York. Since 2015, the company stopped marketing opioids in the U.S. and totally withdrew from the business in 2020.
